STABLE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS WITH EXTENDED RELEASE COATING
    1.
    发明申请
    STABLE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS WITH EXTENDED RELEASE COATING 审中-公开
    具有延伸释放涂层的骨骼肌松弛稳定剂型

    公开(公告)号:WO2013158638A1

    公开(公告)日:2013-10-24

    申请号:PCT/US2013/036775

    申请日:2013-04-16

    Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed along with a method of preparation therefor. The dosage form comprises active core particles which are individually surrounded by a water insoluble polymer coating which lacks plasticizer.

    Abstract translation: 用于以延长或持续释放的方式将骨骼肌松弛剂(例如盐酸环苯扎林)输送到体内的单位剂型,包括一种或多种含药颗粒群(珠粒,丸粒, 颗粒等)与其制备方法一起公开。 剂型包括活性核心颗粒,其由不含增塑剂的水不溶性聚合物涂层包围。

    CHARGE PUMP FOR BUS-POWERED DEVICE
    4.
    发明申请
    CHARGE PUMP FOR BUS-POWERED DEVICE 审中-公开
    总线供电装置的充电泵

    公开(公告)号:WO2007008449A1

    公开(公告)日:2007-01-18

    申请号:PCT/US2006/025522

    申请日:2006-06-29

    CPC classification number: H02M3/155 H02M2001/007 Y10T307/438 Y10T307/625

    Abstract: A charge pump (200) can be used with a bus-powered device connected to a bus. The charge pump (200) comprises a power connection (210) from the bus carrying a DC power signal constrained to not exceed a given current limit and a given voltage limit, a DC-to-DC step-down voltage converter (300), a capacitor (C1), and a DC-to-DC step-up voltage converter (400). The step-down converter (300) has an input connected to the power connection (210) and produces an intermediate signal having a voltage the same or less than the voltage of the power signal. The capacitor (C1) is connected to the output of the step-down converter (300). The step-up converter (400) has an input connected to the output of the step-down converter (300) and to the capacitor (C1), and produces a final output signal having a voltage greater than the given voltage limit. The output of the step-up converter (400) is connected to and provides DC power to the device.

    Abstract translation: 电荷泵(200)可以与连接到总线的总线供电设备一起使用。 电荷泵(200)包括来自总线的电力连接(210),该总线承载被限制为不超过给定电流限制的DC电力信号和给定的电压限制,DC-DC降压电压转换器(300) 电容器(C1)和DC-DC升压电压转换器(400)。 降压转换器(300)具有连接到电力连接(210)的输入端并产生具有与电源信号的电压相同或更小的电压的中间信号。 电容器(C1)连接到降压转换器(300)的输出端。 升压转换器(400)具有连接到降压转换器(300)的输出和电容器(C1)的输入端,并且产生具有大于给定电压极限的电压的最终输出信号。 升压转换器(400)的输出与设备连接并提供直流电力。

    MEASURING VIRAL REVERSE TRANSCRIPTASE ACTIVITY
    6.
    发明申请
    MEASURING VIRAL REVERSE TRANSCRIPTASE ACTIVITY 审中-公开
    测量病毒逆转录酶活性

    公开(公告)号:WO0198541A3

    公开(公告)日:2003-06-19

    申请号:PCT/US0119763

    申请日:2001-06-21

    CPC classification number: C12Q1/48 C12Q1/703

    Abstract: In clinical settings as well as in a drug-discovery context, the impact of an agent that may affect reverse transcriptase (RT) can be measured and even quantified by bringing a sample, which may contain an RT, into contact with an RNA template, a primer complementary to the RNA template, and appropriate oligonucleotide-specific primers, under conditions such that they react, in the presence of RT, to form a cDNA product in inverse proportion to the effect of the agent. The amount of any resultant cDNA product then can be measured. The approach is readily implemented as a real-time, quantitative kinetic assay for RT activity.

    Abstract translation: 在临床环境以及药物发现环境中,可以通过将可能含有RT的样品与RNA模板接触来测量并甚至定量可能影响逆转录酶(RT)的试剂的影响, 与RNA模板互补的引物,以及合适的寡核苷酸特异性引物,在RT的存在下反应,形成与试剂效果成反比的cDNA产物。 然后可以测量任何得到的cDNA产物的量。 该方法很容易实现为RT活性的实时定量动力学测定。

    METHODS FOR GENERATING HIGH TITER HELPER-FREE PREPARATIONS OF RECOMBINANT AAV VECTORS
    9.
    发明申请
    METHODS FOR GENERATING HIGH TITER HELPER-FREE PREPARATIONS OF RECOMBINANT AAV VECTORS 审中-公开
    用于产生重组AAV载体的高度无助剂制剂的方法

    公开(公告)号:WO9911764A3

    公开(公告)日:1999-06-10

    申请号:PCT/US9818600

    申请日:1998-09-04

    CPC classification number: C12N7/00 C12N15/86 C12N2750/14143 C12N2750/14151

    Abstract: This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterelogous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agents that affect viral infectivity and/or replication.

    Abstract translation: 本发明提供了用于生产可用作基因递送载体的高滴度,基本上纯化的重组腺相关病毒(AAV)制备物的方法和组合物。 在载体产生开始时,本发明的AAV生产细胞通常包含一个或多个AAV包装基因,包含异源(即非AAV)目标转基因的AAV载体和辅助病毒如腺病毒。 产生的AAV载体制剂通常是复制缺陷型的,但能够介导感兴趣的转基因(例如治疗基因)向各种组织和细胞中的任何一种的递送。 根据本发明产生的AAV载体制剂也基本上不含辅助病毒以及辅助病毒和细胞蛋白以及其他污染物。 还提供了用于评估病毒感染性和复制以及筛选影响病毒感染性和/或复制的药剂的定量高通量测定。

    GRANULATES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL PRODUCTS CONTAINING THEM
    10.
    发明申请
    GRANULATES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL PRODUCTS CONTAINING THEM 审中-公开
    颗粒,制备它们的方法和含有它们的药用产品

    公开(公告)号:WO2010033179A1

    公开(公告)日:2010-03-25

    申请号:PCT/US2009/005153

    申请日:2009-09-16

    CPC classification number: A61K9/2027 A61K9/2018 A61K9/2059 A61K31/277

    Abstract: A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule optionally contains one or more pharmaceutically acceptable excipients, such as disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The invention also relates to a process for preparing the pharmaceutical granulate and pharmaceutical compositions containing the granulate.

    Abstract translation: 用于药物组合物的颗粒和使用该颗粒的药物组合物制造,其中颗粒包含具有差的水溶性(即小于约1mg / mL)的活性药物成分(API),其与 至少一种药学上可接受的亲水性聚合物。 颗粒任选地含有一种或多种药学上可接受的赋形剂,例如崩解剂,润湿剂,稀释剂,粘合剂,润滑剂,助流剂,着色剂和调味剂。 本发明还涉及制备含有颗粒的药物颗粒和药物组合物的方法。

Patent Agency Ranking